Mise en place du traitement ADCetris® Retrouvez ici le kit de départ

Vous avez décidé d’initier votre patient sur ADCetris®
Nous vous invitons à parcourir les brochures disponibles et les éléments pratiques

New guidelines on treatment and management of Peripheral T-cell lymphomas

Discover the updated recommendations of the Belgian hematology Society (BHS) on diagnosis and treatment of peripheral T-cell lymphomas

CD30+ in Focus is a central hub for clinical data on the approved use of brentuximab vedotin (BV) a CD30-targeted monoclonal anti-body drug conjugate.

Hosted on Medscape, the leading global platform for physicians and healthcare professionals worldwide, CD30+ in focus offers a range of content suited to yourlearning style.

A video from the international key opinion leader prof. Dr. Petros christopoulos on therapeutic sequencing in ALK+ NSCLC.

The International Key Opinion Leader Prof. Dr. Petros Christopoulos presented key data about “The emerging new paradigm in early-stage NSCLC” and “Optimizing the management of ALK+ NSCLC patients”.

Both presentations were followed by a lively discussion with the three Belgian expert panelists, Dr. Mariana Brandao, Prof. Dr. Paul Germonpré and Prof. Nana Frank Aboubakar.

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. 

Video in which Prof.  Mohamad Mohty, Sorbonne hospital St Antoine (Paris) explains the significance of lenalidomide in treating patients with multiple myeloma.
In the video he distinguishes between lenalidomide-sensitive and lenalidomide refractory patients. 

Pharmaceutical class : Proteasome Inhibitors (PI)
Active compound : Ixazomib

NINLARO, in combination with lenalidomide and dexamethasone, is the 1st and only reimbursed Oral PI-triplet combination.

NRd is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.